Back to Search
Study ID

113121

Clinical Study ID

GLP113121

Study Title A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects with Type 2 Diabetes Mellitus
Patient Level Data Study Listed on ClinicalStudyDataRequest.com
Clinicaltrials.gov Identifier NCT01733758
Sponsor GlaxoSmithKline
Collaborators N/A
Phase Phase 3
Study Recruitment Status Completed
Generic Name albiglutide
Trade Name Eperzan,Tanzeum; Tanzeum,Eperzan
Study Indication Diabetes Mellitus, Type 2

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.